RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Transcode Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Transcode Therapeutics has not reported a dividend
No dividend per share appears in Transcode Therapeutics's annual filings since fiscal 2019.